Haoxi Health Technology Limited (HAO) Stock Price & Analysis
Haoxi Health Technology Limited (HAO) — MoonshotScore 32/100 (Weak band), calculated Oct 5, 2026. Price $2.63 (-2.41%), as of the Oct 5, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Haoxi Health Technology Limited · HAO
Haoxi Health Technology Limited provides online marketing solutions in China, primarily serving the healthcare industry. The company focuses on online short video marketing and customized advertising solutions across various online media platforms.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore v2 · Haoxi Health Technology (HAO)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fortress balance sheet, but bottom-tier quality, and the price trend has turned against it. Business Quality: Poor; Financial Safety: Fortress; Valuation: Full; Growth Durability: Growing; Momentum: Falling.
- quarterly revenue $34M (Q2 FY2026, quarter ended Dec 2025)
- Altman Z 4.02 · Piotroski F 3
- ROE -16.6% · ROA -13.4% · current ratio 3.45
Holding back: weak fundamentals, weak price trend
Helping: balance-sheet strength
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 33 | Weak | |
| 33 | Weak | |
| 33 | Weak | |
| 33 | Weak | |
| 33 | Weak | |
| 32 | Weak |
The score was 32 in the stored Oct 4, 2026 snapshot and remains 32 in the current publication computed Oct 5, 2026 (0); the largest pillar moves were Growth Durability -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $2.63 | |
| Change on the day | -2.41% | |
| 52-week range | $2.61 – $4352.00 | |
| Price / earnings (trailing) | 0.82 | |
| Shares traded on the day | 40.2K |
Price & events
Other perspectives
Council score for Haoxi Health Technology (HAO): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the HAO film — every key number, told as a short cinematic story
~2 min · open the film
What is Haoxi Health Technology (HAO), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Haoxi Health Technology Limited (HAO) is the company analyzed here. It employs 26 people and is led by Zhen Fan. In Q2 FY2026 it reported revenue of $34M and net income of -$7M.
What do the latest results show for Haoxi Health Technology (HAO)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $34M.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $34M | -$7M | -$30.67 (diluted) |
| Q4 FY2025 | $9M | $4M | $28.37 (diluted) |
| Q2 FY2025 | $24M | -$232,533 | -$0.26 (diluted) |
| Q4 FY2024 | $25M | $529,802 | $0.84 (diluted) |
What are the financial strengths and risks for Haoxi Health Technology (HAO)?
Short answer
The MoonshotScore pillars rate balance-sheet strength as strengths. What is holding it back is weak fundamentals, weak price trend. The distress and quality screens read Altman Z 4.02 · Piotroski F 3. Trailing ratios: ROE -16.6% · ROA -13.4% · current ratio 3.45.
Data-derived red flags
- Negative return on equity (-16.6%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
How does Haoxi Health Technology compare with its peers?
Short answer
Haoxi Health Technology's score ranks 9th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $5.38 Oct 5, 2026 | $55.3M | 60 5-pillar Oct 5, 2026 | |
| $4.79 Oct 5, 2026 | $60.2M | 57 5-pillar Oct 5, 2026 | |
| $1.55 Oct 5, 2026 | $46.1M | 56 5-pillar Oct 5, 2026 | |
| $1.42 Oct 5, 2026 | $26.5M | 55 5-pillar Oct 5, 2026 | |
| $4.70 Oct 5, 2026 | $18.8M | 50 5-pillar Oct 5, 2026 | |
| $0.76 Oct 5, 2026 | $37.2M | 44 5-pillar Oct 5, 2026 | |
| $4.54 Oct 5, 2026 | $33.7M | 42 5-pillar Oct 5, 2026 | |
| $5.08 Oct 5, 2026 | $8.71M | 33 5-pillar Oct 5, 2026 | |
| Haoxi Health Technology (HAO) — this page | $2.63 | — | 32 |
| $4.44 Oct 5, 2026 | $75.0M | 26 5-pillar Oct 5, 2026 | |
| $1.58 Oct 5, 2026 | $5.72M | 22 5-pillar Oct 5, 2026 | |
| $0.53 Oct 5, 2026 | $9.15M | 22 5-pillar Oct 5, 2026 | |
| $1.28 Oct 5, 2026 | $57.2M | 22 5-pillar Oct 5, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 1
- Identified insiders
- 1
- Purchases
- 1
- Sales
- 0
- Other transactions
- 0
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Common Questions About HAO
These answers are editorial: 1 of these 9 answers is drawn from the HAO research dossier (written May 31, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for HAO?
HAO carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Haoxi Health Technology Limited provides online marketing solutions in China, primarily serving the healthcare industry.
Is HAO a good stock to buy?
Stock Expert AI does not rate HAO buy, sell or hold. Haoxi Health Technology Limited carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the HAO stock price today?
The last price recorded on this page for Haoxi Health Technology Limited (HAO) is $2.63, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about HAO stock?
There is no analyst coverage information provided. Therefore, there is no analyst consensus, valuation metrics, or growth considerations available. Further research would be needed to determine analyst sentiment and potential investment considerations.
What are the key factors to evaluate for HAO?
Haoxi Health Technology Limited (HAO) holds a MoonshotScore in the low range. P/E: 0.82x. Haoxi Health Technology Limited operates in the online marketing solutions sector in China, focusing on the healthcare industry. Not financial advice.
How frequently does HAO data refresh on this page?
HAO's price is the last quote we recorded, from the Oct 5, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven HAO's recent stock price performance?
Haoxi Health Technology Limited (HAO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on the healthcare industry provides a specialized market position. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HAO overvalued or undervalued right now?
Haoxi Health Technology Limited (HAO) trades at 0.82x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research HAO before investing?
Before investing in Haoxi Health Technology Limited (HAO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 31, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (16 figures)
The 16 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 9 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $2.63 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T21:44:44.504Z. | |
px.change | Change on the day | -2.41% | FMP | Financial Modeling Prep (FMP) · quote | |
px.change_abs | Change on the day, in dollars | −$0.065 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $34M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.pe | Price / earnings (trailing) | 0.82 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 40.2K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_income | Net income, Q2 FY2026 | -$7M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
own.insiders | Insider transactions via FMP | 1 transactions · 1 purchases, 0 sales, 0 other transactions · 1 identified insiders · most recent available transactions | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 5 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.scores | Distress and quality screens | Altman Z 4.02 · Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-03 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -16.6% · ROA -13.4% · current ratio 3.45 | — | UNRECORDED | Stored key metrics — Date unknown |
px.range52 | 52-week range | $2.61 – $4352.00 | UNRECORDED | Stored company-profile observation — Captured 2026-09-30 | |
id.employees | Employees | 26 | UNRECORDED | Stored company-profile observation — Captured 2026-09-30 | |
id.ceo | Chief executive | Zhen Fan | UNRECORDED | Stored company-profile observation — Captured 2026-09-30 |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 32 of 100 · Weak · pillars 6 / 91 / 52 / 67 / 4 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 32 (stored snapshot Oct 4, 2026) → 32 (current publication computed Oct 5, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.